Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Phase I Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors Who Have Failed Approved Standard Therapies

Next Previous
Trial Profile

Open-label, Phase I Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors Who Have Failed Approved Standard Therapies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NYH 817100 (Primary) ; NYH100P (Primary) ; NYH817G (Primary)
  • Indications Brain cancer; Carcinoma; Gastric cancer; Lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Haim Bio Co

Most Recent Events

  • 17 Feb 2020 New trial record
  • 28 Jan 2019 According to a Haim Bio Co media release, the clinician who will conduct the first phase of clinical trials will be with Prof. Hye-Jin Choi, Professor Jae-Ho Jung and Professor Seok-Koo Ka
  • 28 Jan 2019 According to a Haim Bio Co media release,the company will submit an IND to non-clinical CROs and the Ministry of Food and Drug Safety around March. After the KFDA's IND approval, the company will conduct phase 1 clinical trials at Yonsei University Severance Hospital and the National Cancer Center along with clinical CRO. Phase I clinical trials are expected in the middle of this year (2019), when the KFDA is approved for IND

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top